Rollout Begins Of Trump's Drug Blueprint
Source: Life Science Leader
By John McManus, The McManus Group
The Trump administration disrupted the typically sleepy August recess with a frenetic release of proposals that implement components of its “blueprint” on drug pricing. The proposals are intended to strengthen the negotiating leverage of Medicare plans over pharmaceutical manufacturers, but physician and patient advocates expressed concern that they may result in impaired patient access to needed drug therapy.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more